Prevymis (letermovir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   32 Trials   32 Trials   1662 News 


«12...13141516171819202122232425»
  • ||||||||||  Letermovir for Primary Cytomegalovirus Prevention in Haploidentical Stem Cell Transplant Recipients (World Center Marriott - Palms & Cypress Foyers) -  Dec 18, 2019 - Abstract #TCTASTCTCIBMTR2020TCT_868;    
    Our study demonstrated the efficacy of letermovir as primary prophylaxis among CMV seropositive haploidentical recipients. However, significant CMV reactivation was seen beyond day 100 and future studies need to be conducted on the ideal duration of prophylaxis in this high-risk population.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
    Review, Journal:  CMV Prevention and Treatment in Transplantation: What's New in 2019. (Pubmed Central) -  Nov 20, 2019   
    Letermovir was recently approved for CMV prevention in HCT recipients...Maribavir is in late stages of development for CMV treatment and may provide a safer alternative to currently available anti-CMV drugs...In recent years, major advances have been made in CMV prevention and treatment in transplant recipients. Rigorous research is ongoing and is anticipated to further impact our ability to improve outcomes in this population.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection (clinicaltrials.gov) -  Nov 8, 2019   
    P2,  N=32, Recruiting, 
    In addition, midazolam interactions with letermovir at therapeutic doses were also simulated to confirm that letermovir is a moderate CYP3A inhibitor. Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Dec 2020
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_6236;    
    CMV reactivation is associated with increased risk of developing grade 2-4 acute GVHD and higher NRM . We conclude that also in the platform of haplo-SCT with PT-Cy, letermovir prophylaxis should be given not to all patients, but mainly to CMV seropositive recipients, that probably may benefit the most in terms of CMV reactivation, acute GVHD incidence and NRM.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Management of cytomegalovirus infection after hematopoietic stem cell transplantation (Pubmed Central) -  Oct 28, 2019   
    However, the onset of CMV infection/disease as either a breakthrough infection or after the discontinuation of letermovir is still problematic. In this section, the management tips for CMV infection after allogeneic HSCT have been summarized.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Vistide (cidofovir) / Gilead
    Journal:  An overview of letermovir: a cytomegalovirus prophylactic option. (Pubmed Central) -  Oct 27, 2019   
    Expert opinion: LTV safety and efficacy are promising. However, long-term adverse events and the emergence of drug-resistant HCMV strains must be investigated in extended clinical trials prior to drawing final conclusions.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Clinical, Journal:  Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. (Pubmed Central) -  Oct 27, 2019   
    An investigational agent, maribavir, exerts its anti-CMV effect through UL97 inhibition, and its safety profile is under clinical evaluation...In addition to antiviral drugs, reduction of immunosuppression is often generally needed in the management of HCMV infection, but with a potential risk of allograft rejection or graft-versus-host disease. The use of HCMV-specific or non-specific intravenous immunoglobulins remains debated, while adoptive HCMV-specific T cell therapy remains investigational, and associated with unique set of adverse effects.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Xofluza (baloxavir marboxil) / Roche, Shionogi
    Journal:  Antiviral therapy for general practitioners (Pubmed Central) -  Oct 18, 2019   
    This article summarizes actual and available therapy. New treatments arrived recently on the market or are being developed : HCV can now be treated with a high success rate, baloxavir against the flu, a new zoster vaccine will probably soon be available in Switzerland and letermovir improves CMV prophylaxis in the case of hematopoietic stem cell transplant.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Vistide (cidofovir) / Gilead
    Letermovir Therapy for Resistant Cytomegalovirus in a Kidney Transplant Recipient: Case Report (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4696;    
    Letermovir for salvage therapy has been reported but widespread use has not been adopted due to the low barrier to resistance. Our unconventional approach using combination foscarnet and ganciclovir treatment then switching to letermovir presents a possible niche for agent’s use to sustain suppression of a multidrug resistant CMV.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
    Treatment of Valganciclovir-Resistant Cytomegalovirus with Letermovir (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4684;    
    P2
    Here we present a case of an individual with proven UL97 mutation-driven ganciclovir-resistant CMV who developed severe side effects precluding further use of foscarnet and was started on Letermovir for treatment of CMV. CMV viral load improved to barely detectable levels on treatment with letermovir alone, without marrowsuppressive or nephrotoxic side effects.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Review, Journal:  Meeting report: 31st International Conference on Antiviral Research. (Pubmed Central) -  Oct 8, 2019   
    The 31st ICAR successfully promoted new discoveries in antiviral research and drug development. The 32nd ICAR will be held in Baltimore, Maryland, USA, May 6-10, 2019.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Preclinical, Journal:  In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. (Pubmed Central) -  Oct 8, 2019   
    Using MacSynergy II (a statistical package that measures enhancement or lessening of effect relative to zero/additive), select drug combination studies demonstrated combination indices ranging from 160 to 372 with 95% confidence intervals greater than zero indicating that these combinations elicit a synergistic enhancement of effect against HCMV in vitro. These data suggest that administration of a viral DNA polymerase inhibitor, MBV, and/or a viral terminase inhibitor in combination has the potential to address the resistance/cross-resistance problems associated with currently available therapeutics.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
    Preclinical, Journal:  A New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by in vitro Exposure to Letermovir and Ganciclovir. (Pubmed Central) -  Sep 28, 2019   
    UL56 substitutions V236A, L328V and A365S were shown to confer borderline or low-grade letermovir resistance, while C25F conferred 5.4-fold increased letermovir resistance (EC50) by itself and 46-fold in combination with V231L. The evolution of resistance mutations sooner in UL56 than in UL54 or UL97 is consistent with prior in vitro observations, and UL56 codon 25 is a genetic locus for letermovir resistance distinct from those previously described.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
    Review, Journal:  New therapies for human cytomegalovirus infections. (Pubmed Central) -  Sep 26, 2019   
    Existing drugs will also be discussed and some of the more promising candidates will be reviewed with an emphasis on those progressing through clinical studies. The in vitro and in vivo antiviral activity, spectrum of antiviral activity, and mechanism of action of new compounds will be reviewed to provide an update on potential new therapies for HCMV infections that have progressed significantly in recent years.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
    Journal:  Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity. (Pubmed Central) -  Sep 26, 2019   
    A novel anti-HCMV drug, letermovir, has been approved recently, so that improved therapy options are available...In essence, we provide novel evidence as follows: (i) screening hit SC88941 is highly active in inhibiting HCMV replication in primary human fibroblasts with an EC value of 0.20 ± 0.01 μM in the absence of cytotoxicity, (ii) inhibition occurs at the early-late stage of viral protein production and shows reinforcing effects upon LMV cotreatment, (iii) among the viruses analyzed, antiviral activity was most pronounced against β-herpesviruses (HCMV, HHV-6A) and intermediate against adenovirus (HAdV-2), (iv) induction of SC88941 resistance was not detectable, thus differed from the induction of ganciclovir resistance, (v) a linker-coupled model compound was used for mass spectrometry-based target identification, thus yielding several drug-binding target proteins and (vi) a first confocal imaging approach used for addressing intracellular effects of SC88941 indicated qualitative and quantitative alteration of viral protein expression and localization. Thus, our findings suggest a multifaceted pattern of compound-target binding in connection with an unusual mode of action, opening up further opportunities of antiviral drug development.
  • ||||||||||  Vistide (cidofovir) / Gilead, maribavir (TAK-620) / Takeda, GSK
    Journal, Combination therapy:  Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Pubmed Central) -  Sep 22, 2019   
    Baseline virus and representative drug-resistant mutants were tested. According to the volume of synergy at 95% confidence, maribavir showed additive interactions with foscarnet, cidofovir, letermovir and GW275175X when tested against wild type and mutant viruses, strong antagonism with ganciclovir, and strong synergy with rapamycin, the latter suggesting a potentially useful therapeutic combination.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma (Exhibition area) -  Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_645;    
    A novel RPA-based M1 stage set incorporating baseline plasma EBV DNA had a significantly better survival prediction, providing important values on prognosis and treatment decision making.Legal entity responsible for the study: The authors. Funding: Has not received any funding.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    PK/PD data, Journal:  Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics. (Pubmed Central) -  Sep 16, 2019   
    Letermovir coadministration with COC resulted in an increase in LNG and EE exposure in healthy adult women; however, levels were within the established safety margins. There was no decrease in LNG or EE exposure with no apparent risk of contraceptive failure on coadministration of letermovir and COC..